Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 81,859

Document Document Title
WO/2018/070940A1
The present disclosure is directed to an injectable composition which is capable of delivering a controlled and sustained amount of at least one 5α-reductase inhibitor to a subject. The injectable composition comprises a polymer solutio...  
WO/2018/069467A1
This invention relates to an immunoconjugate comprising interleukin-4 (IL4) and two antibody molecules which bind an extra-cellular matrix component associated with neoplastic growth, angiogenesis, and/or tissue remodelling, such as the ...  
WO/2018/069408A1
The present invention relates to compositions of extracellular vesicles (EVs) which are characterized by a strong proangiogenic activity and are effective in the therapeutic treatment of ischemic diseases and ischemic injuries or in woun...  
WO/2018/071620A1
There are described RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical composi...  
WO/2018/071687A1
The present disclosure provides compositions and methods for treating chronic itch.  
WO/2018/064950A1
The present invention relates to a stem cell gel preparation for maintaining frozen cell activity and a stem cell gel preparation containing stem cells. The gel preparation comprises the following components in percentage by weight: 1%-3...  
WO/2018/066580A1
The purpose of the present invention is to provide a wound healing agent active ingredient which can be applied to the provision of a wound healing agent that contains a single active ingredient, has high biocompatibility and an activity...  
WO/2018/066707A1
Provided are: a novel aging inhibitor, soft-tissue calcification inhibitor, and lung tissue destruction inhibitor; food and beverage products, pharmaceutical products, and cosmetic products which include said inhibitors; and a method for...  
WO/2018/066704A1
[Problem] To provide a safe compound having originated from the natural world, the compound being usable in the skin care fields, for example, skin whitening, acne prevention, anti-inflammation, wrinkle prevention, and skin moisturizatio...  
WO/2018/064985A1
A fullerene and an application of a derivative of fullerene utilized in preparing a product for promoting hair growth. Also provided is a Chinese medicine composition containing fullerene and a derivative thereof for resisting head infec...  
WO/2018/065545A1
The present invention relates to the use of 6-O-(C8-C20 alkyl ester) of 1-O-(C1-C6 alkyl)-β-D-glucoside and in particular 6-O-lauroyl of 1-O-n-butyl-β-D-glucoside as an agent for protecting the skin and/or mucous membranes. The inventi...  
WO/2018/058261A1
A traditional Chinese medicine composition for treating psoriasis and a preparation method thereof. The composition consists of the following traditional Chinese herbs and the respective parts by weight: 20-80 parts of Radix Rumicis Japo...  
WO/2018/059534A1
Disclosed are a crystal form and a salt form of and a preparation method for a tyrosine kinase inhibitor.  
WO/2018/060213A1
The present invention relates to pre-formulations comprising: a) at least one di-acyl lipid; b) at least one phospholipid; c) at least one biocompatible, organic solvent; d) an alkyl ammonium EDTA salt; and e) at least one somatostatin r...  
WO/2018/059331A1
The present invention relates to a polyamide compound and a use thereof; specifically, the present invention relates to a type of polyamide compound (which preferably contains one or more amide bonds formed by the condensation of same or...  
WO/2018/060567A1
Process with the aim of preventing or slowing the appearance of unattractive signs, generated by the pollutants present in the atmosphere, on the skin, the scalp, the hair or the mucous membranes, or indeed of eliminating them, comprisin...  
WO/2018/060870A1
The invention relates to a topical pharmaceutical composition comprising effective amount of ivermectin as an active agent, process of preparation thereof and method of treating dermatological conditions such as inflammatory lesions of r...  
WO/2018/062427A1
The use of at least any one of astaxanthin and an astaxanthin-containing composition for reducing the progression of damage caused to human skin by an external factor, and a method for reducing the progression of damage caused to human s...  
WO/2018/060866A1
The invention relates to novel oral pharmaceutical compositions of retinoid as an active ingredient. The compositions comprise one or more mono and/or di glycerides, and one or more vegetable oils. Methods of preparing such compositions ...  
WO/2018/060174A1
The invention relates to substituted benzimidazoles of formula (I), to the use thereof for treating and/or preventing diseases, and to the use thereof for producing drugs for treating and/or preventing diseases, in particular for treatin...  
WO/2018/060212A1
The present invention relates to mixtures comprising: i) at least one lipid and/or at least one oil; and ii) an alkyl ammonium EDTA salt; wherein the mixture has a water content in the range of 0 to 1.0 wt%. The invention further relates...  
WO/2018/063010A1
The invention relates to a novel lupeol derivative, which is the ester of 4-picolinic acid (isonicotinic acid) and 20(29)-lupen-3.beta.-ol (lupeol), having structural Formula (1). The novel lupeol derivative is a result of modification o...  
WO/2018/060764A1
A topical formulation containing a phytotherapeutic combination of Tilia tomentosa, Cedrus libani, Viola tricolor, Ribes nigrum, Secale cereale, Lavanda officinalis essential oil, bergamot essential oil and cajeput essential oil, prefera...  
WO/2018/062382A1
Provided are novel crystals of [2-(1-methyl-1H-pyrazol-4-yl)-6-(morphlin-4-yl)-9H-purin-8-y l][4-(morpholin-4-yl)piperidin-1-yl]methanone and a pharmaceutically acceptable salt thereof having advantageous characteristics. [2-(1-Methyl-1H...  
WO/2018/060994A1
This disclosure relates to a method for producing a native, non-soluble, non-crossed- linked extracellular matrix, containing collagens, mainly Type II collagen, derived from jellyfish sources. A short extraction procedure with acid and ...  
WO/2018/055058A1
A pharmaceutical composition comprising polyunsaturated long-chain ketones and a silicone vehicle or a blend of silicone vehicles. The composition has utility in the treatment and prevention of inflammatory conditions including skin diso...  
WO/2018/055360A1
A molecular complex comprising a therapeutic agent and a controlled release construct, the controlled release construct comprising a primary matrix conjugation site which is linked to an cell adhesive site, via a binding region and optio...  
WO/2018/056268A1
Provided is an agent for the treatment and/or prevention of inflammatory eye disorder, containing (3S, 4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazine-8-yl) -N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxylic acid amide or a salt th...  
WO/2018/054229A1
A micro-nucleic acid acne-removing composition consists of the following components by weight percent: 0.001-0.5% of micro-nucleic acid molecules and 99.50-99.999% of a cosmetic excipient or an externally applied agent excipient, wherein...  
WO/2018/053643A1
Described herein are compositions and methods for modulating cellular senescence of a cell or induction of the senescence-associated secretory phenotype (SASP) in a cell. The methods generally comprise modulating the level or activity of...  
WO/2018/057588A1
Disclosed are chemical entities which are compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, R1, R2, E, n and Z are as defined herein. These chemical entities are useful as inhibitors of the PAR-2 sig...  
WO/2018/057776A1
The present invention provides methods for treating moderate-to-severe or severe atopic dermatitis (AD). The methods of the present invention comprise administering to a subject in need thereof one or more doses of an interleukin-4 recep...  
WO/2018/056470A1
The purpose of the present invention is to provide a novel compound that selectively damages cells that have become mesenchymal cells by epithelial-mesenchymal transition. Compounds, etc., represented by formula (I). [In the formula, R1 ...  
WO/2018/054354A1
Provided is an application of an SRC homology region 2-containing protein tyrosine phosphatase-1 agonist as represented by formula (I) in preparation of drugs for treating and reducing fibrosis. Preferably, the agonist is SC-43; the fibr...  
WO/2018/053641A1
The present disclosure relates to methods for reducing scarring of wounds. The methods comprising topically applying on the wound a biophotonic composition followed by illumination of the applied biophotonic composition with actinic ligh...  
WO/2018/051895A1
Provided is a drug composition and food composition for treating or preventing a skin disease caused by the abnormal proliferation of a skin bacterium or caused by pathogenic microbe infection. This composition includes lactic acid bacte...  
WO/2018/051183A1
Described herein are methods for treating one or more skin conditions by administering, via the sublingual or buccal route, a composition comprising substituted or unsubstituted diindolylmethane. In particular, methods are provided for i...  
WO/2018/050286A1
The invention relates to compounds which are suitable for the treatment of cancer, an immune disease, Parkinson's disease, Cardiac Hypertrophy or Type-2 diabetes and to pharmaceutical compositions containing such compounds. The invention...  
WO/2018/052082A1
This Lin28a activator includes, as an active ingredient, a polysaccharide which contains at least one substance selected from the group consisting of ribose, xylose, and derivatives of each. A monocyte dedifferentiation inducer includes,...  
WO/2018/053004A2
Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions com...  
WO/2018/049557A1
Materials and methods for altering the skin microbiota of a subject with an amenable skin condition are provided. Amenable skin conditions include healthy skin and skin exhibiting atopic dermatitis (with or without lesions), skin dysbios...  
WO/2018/052147A1
A topical composition having foamability and at least including water, a hydroxide, and a thickener. Said hydroxide is selected from alkali metal hydroxides, alkali earth metal hydroxides, hydroxides of metals belonging to group 2 of the...  
WO/2018/051325A1
Provided are pharmaceutical foam compositions comprising a peptone, a peptide hydrolysate or an enzymatically-hydrolyzed protein prepared by enzymatic hydrolysis of a full-length protein; methods of preparation and uses thereof.  
WO/2018/052443A1
A drug delivery composition is disclosed which includes a triple salt proxy functional group and at least one amino acid functional group. A method of forming the drug delivery composition includes reacting a triple salt with at least on...  
WO/2018/050276A1
Pharmaceutical or cosmetic composition for the prevention and treatment of hair loss this solution being made up by H2O and NaCI solution and containing inositol (I) 1,4,5-phosphate (C6H15O15P3) and (II) biotin (C10H16N2O3S).  
WO/2018/049556A1
Materials and methods for selectively increasing the diversity of the skin microbiota of a subject with an amenable skin condition are provided in disclosing methods for using compositions comprising a zinc compound, a biocompatible surf...  
WO/2018/049558A1
Materials and methods for improving the appearance of a subject with an amenable skin with a composition comprising a zinc compound, a biocompatible surfactant and a lipid are provided. Amenable skin includes healthy skin and skin exhibi...  
WO/2018/051296A2
The present invention relates in particular to a pharmaceutical composition comprising the non-saponifiable moieties obtained from lipids of natuiral vegetable origin for use in the treatment of those rheumatic diseases, such as rheumato...  
WO/2018/051972A1
Provided is a method for separating the four optical isomers of Nahlsgen. According to the present invention, a method for producing a mixture of D-2-amino-4-[(Rp)-(3-carboxymethylphenoxy)(methoxy)phosphory l]butanoic acid hydrate and L-...  
WO/2018/045417A1
The present invention relates generally to an assay for use in a clinical protocol to manage the extent of scarring or potential scarring associated with wound healing in human and animal subjects. The assay comprises an assessment of th...  

Matches 1 - 50 out of 81,859